Gantenerumab didn’t improve cognitive decline in two trials that followed 2,000 people for over 2 years. Patients treated with gantenerumab had a slowing of clinical decline in the GRADUATE and GRADUATE II trials of –0.31, and –0.19, respectively, from baseline on the CDR-SB scale, representing a relative reduction of 8% and 6%, respectively, compared with placebo. The level of amyloid-β removal was lower than anticipated.